Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage

American Heart Journal

Volumn 141, Issue 5, 2001, Pages 742-750

  Giugliano, Robert P ^a   McCabe, Carolyn H ^a   Antman, Elliott M ^a   Cannon, Christopher P ^a   Van De Werf, Frans ^b   Wilcox, Robert G ^c   Braunwald, Eugene ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c University Hospital

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; STREPTOKINASE; TENECTEPLASE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; DRUG INDUCED DISEASE; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035033834     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.114975     Document Type: Article

References (51)

1. Bleeding during thrombolytic therapy for acute myocardial infarction: Mechanisms and management
2. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis
3. Stroke complicating thrombolytic therapy of acute myocardial infarction
4. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study: Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial
5. Stroke and acute myocardial infarction in the thrombolytic era: Clinical correlates and long-term prognosis
6. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-I trial: Global Use of Strategies to Open Occluded Coronary Arteries
7. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients: Fibrinolytic Therapy Trialists' (FTT) Collaborative Group
8. Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors
9. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: Participants in the National Registry of Myocardial Infarction 2
10. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis
11. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy
12. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke: The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study
13. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction: A randomized trial
14. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage: Thrombolytic Predictive Instrument (TPI) Project results
15. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial
16. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
17. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes: The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators
18. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes: The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators
19. Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: Results from TIMI 10B and ASSENT I
20. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction: Heparin-Aspirin Reperfusion Trial (HART) Investigators
21. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
22. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial
23. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
24. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
25. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction: ISIS-3 (Third International Study of Infarct Survival) Collaborative Group
26. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction: The GUSTO investigators
27. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials
28. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
29. Coronary thrombolysis
30. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial: Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators
31. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction: The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators
32. A comparison of reteplase with alteplase for acute myocardial infarction: The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators
33. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial: Assessment of the Safety and Efficacy of a New Thrombolytic Investigators
34. Intravenous nPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison of singe bolus lanoteplase vs accelerated alteplase vs for the treatment of patients with acute myocardial infarction
35. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial: The ASSENT-1 Investigators
36. Risk of intracranial hemorrhage with accelerated tPA: Importance of the heparin dose
37. Omission of heparin bolus lowers rate of intracranial hemorrhage with lanoteplase
38. Two new factors on blood coagulation: Heparin and pro-antithrombin
39. A case for limiting heparin use in combination with t-PA: Pooled analysis of GUSTO-3, ASSENT-2, InTIME for intracranial hemorrhage
40. Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy
41. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: A meta-analysis
42. An experimental model of intracranial hemorrhage during thrombolytic therapy with t-PA
43. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial
44. Factors associated with major hemorrhage during reperfusion therapy in acute myocardial infarction: A TIMI 14 substudy
45. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: The EPI-LOG Investigators
46. A new regimen for heparin use in acute coronary syndromes
47. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction: The RAPID II Investigators
48. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial: The TIMI 14 Investigators
49. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
50. Establishing a therapeutic range for heparin therapy
51. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT): Implications in heparin monitoring by APTT